Ken Griffin Rhythm Pharmaceuticals, Inc. Put Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$40.81 - $55.0 $228,536 - $308,000	-5,600 Reduced 30.94%	12,500 $654,000
Q2 2024 Aug 14, 2024	SELL	$35.41 - $44.37 $123,934 - $155,295	-3,500 Reduced 16.2%	18,100 $743,000
Q1 2024 May 15, 2024	BUY	$39.12 - $52.44 $320,784 - $430,008	8,200 Added 61.19%	21,600 $935,000
Q4 2023 Feb 14, 2024	BUY	$21.39 - $49.64 $156,147 - $362,372	7,300 Added 119.67%	13,400 $615,000
Q3 2023 Nov 14, 2023	SELL	$15.81 - $27.8 $47,430 - $83,400	-3,000 Reduced 32.97%	6,100 $139,000
Q2 2023 Aug 14, 2023	SELL	$16.32 - $21.15 $190,944 - $247,454	-11,700 Reduced 56.25%	9,100 $150,000
Q1 2023 May 15, 2023	BUY	$16.88 - $34.24 $285,272 - $578,656	16,900 Added 433.33%	20,800 $371,000
Q4 2022 Feb 14, 2023	BUY	$22.21 - $30.25 $86,619 - $117,975	3,900 New	3,900 $113,000

191

67.3M

834K

78.6K

Ticker RYTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,720,000
Market Cap $3.15B
Description
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.